View in EDS

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Saved in:
Bibliographic Details
Title: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Authors: Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au., Garnett-Benson C; Bristol Myers Squibb, Princeton, NJ, USA., Dolfi S; Bristol Myers Squibb, Princeton, NJ, USA., Ascierto PA; Istituto Nazionale dei Tumori IRCCS 'Fondazione G. Pascale', Napoli, Italy., Guo J; Peking University Cancer Hospital & Institute, Beijing, China., Tarhini AA; Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Chandra S; Northwestern University, Chicago, IL, USA., Muñoz-Couselo E; Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., de Melo AC; Brazilian National Cancer Institute, Rio de Janeiro, Brazil., Callahan M; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gogas H; National and Kapodistrian University of Athens, Athens, Greece., Dummer R; University of Zurich, Zurich, Switzerland., Schadendorf D; University Hospital Essen, National Center for Tumor Diseases (NCT-West), Campus Essen, German Cancer Consortium, Campus Essen, and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany., Koelblinger P; Paracelsus Medical University, Salzburg, Austria., Quereux G; CHU Nantes, Nantes University and Immunology and New Concepts in ImmunoTherapy (INCIT), Nantes, France., Thomas I; EDOEAP, Athens, Greece., Yu JX; Bristol Myers Squibb, Princeton, NJ, USA., Fisher A; Bristol Myers Squibb, Princeton, NJ, USA., Wang B; Bristol Myers Squibb, Princeton, NJ, USA., Djidel P; Bristol Myers Squibb, Princeton, NJ, USA., Chouzy A; Bristol Myers Squibb, Princeton, NJ, USA., Semaan M; Bristol Myers Squibb, Princeton, NJ, USA., Chen B; Bristol Myers Squibb, Princeton, NJ, USA., Cheong AMY; Bristol Myers Squibb, Uxbridge, UK., Tawbi HA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Nature medicine [Nat Med] 2025 Dec; Vol. 31 (12), pp. 4301-4309. Date of Electronic Publication: 2025 Oct 18.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41109920
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Long+GV%22">Long GV</searchLink>; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.<br /><searchLink fieldCode="AU" term="%22Garnett-Benson+C%22">Garnett-Benson C</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Dolfi+S%22">Dolfi S</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; Istituto Nazionale dei Tumori IRCCS 'Fondazione G. Pascale', Napoli, Italy.<br /><searchLink fieldCode="AU" term="%22Guo+J%22">Guo J</searchLink>; Peking University Cancer Hospital & Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Tarhini+AA%22">Tarhini AA</searchLink>; Moffitt Cancer Center & Research Institute, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Chandra+S%22">Chandra S</searchLink>; Northwestern University, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Muñoz-Couselo+E%22">Muñoz-Couselo E</searchLink>; Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Del+Vecchio+M%22">Del Vecchio M</searchLink>; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22de+Melo+AC%22">de Melo AC</searchLink>; Brazilian National Cancer Institute, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Callahan+M%22">Callahan M</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Gogas+H%22">Gogas H</searchLink>; National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Dummer+R%22">Dummer R</searchLink>; University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schadendorf+D%22">Schadendorf D</searchLink>; University Hospital Essen, National Center for Tumor Diseases (NCT-West), Campus Essen, German Cancer Consortium, Campus Essen, and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Koelblinger+P%22">Koelblinger P</searchLink>; Paracelsus Medical University, Salzburg, Austria.<br /><searchLink fieldCode="AU" term="%22Quereux+G%22">Quereux G</searchLink>; CHU Nantes, Nantes University and Immunology and New Concepts in ImmunoTherapy (INCIT), Nantes, France.<br /><searchLink fieldCode="AU" term="%22Thomas+I%22">Thomas I</searchLink>; EDOEAP, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Yu+JX%22">Yu JX</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Fisher+A%22">Fisher A</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Wang+B%22">Wang B</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Djidel+P%22">Djidel P</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chouzy+A%22">Chouzy A</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Semaan+M%22">Semaan M</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chen+B%22">Chen B</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Cheong+AMY%22">Cheong AMY</searchLink>; Bristol Myers Squibb, Uxbridge, UK.<br /><searchLink fieldCode="AU" term="%22Tawbi+HA%22">Tawbi HA</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2025 Dec; Vol. 31 (12), pp. 4301-4309. <i>Date of Electronic Publication: </i>2025 Oct 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41109920
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-025-04032-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4301
    Titles:
      – TitleFull: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Long GV
      – PersonEntity:
          Name:
            NameFull: Garnett-Benson C
      – PersonEntity:
          Name:
            NameFull: Dolfi S
      – PersonEntity:
          Name:
            NameFull: Ascierto PA
      – PersonEntity:
          Name:
            NameFull: Guo J
      – PersonEntity:
          Name:
            NameFull: Tarhini AA
      – PersonEntity:
          Name:
            NameFull: Chandra S
      – PersonEntity:
          Name:
            NameFull: Muñoz-Couselo E
      – PersonEntity:
          Name:
            NameFull: Del Vecchio M
      – PersonEntity:
          Name:
            NameFull: de Melo AC
      – PersonEntity:
          Name:
            NameFull: Callahan M
      – PersonEntity:
          Name:
            NameFull: Gogas H
      – PersonEntity:
          Name:
            NameFull: Dummer R
      – PersonEntity:
          Name:
            NameFull: Schadendorf D
      – PersonEntity:
          Name:
            NameFull: Koelblinger P
      – PersonEntity:
          Name:
            NameFull: Quereux G
      – PersonEntity:
          Name:
            NameFull: Thomas I
      – PersonEntity:
          Name:
            NameFull: Yu JX
      – PersonEntity:
          Name:
            NameFull: Fisher A
      – PersonEntity:
          Name:
            NameFull: Wang B
      – PersonEntity:
          Name:
            NameFull: Djidel P
      – PersonEntity:
          Name:
            NameFull: Chouzy A
      – PersonEntity:
          Name:
            NameFull: Semaan M
      – PersonEntity:
          Name:
            NameFull: Chen B
      – PersonEntity:
          Name:
            NameFull: Cheong AMY
      – PersonEntity:
          Name:
            NameFull: Tawbi HA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1